<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="confer">
            <roleset id="confer.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x09;&#x09;// mechanism, process, entity(imply to condition or property in that entity) // &#x0A;" />
                    <role n="1" descr="given biological property&#x09;&#x0A;" />
                    <role n="2" descr="entity receiving the biological property&#x09;         // gene product, celll, tissue, etc. //&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>AGATT transfection (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer resistance to alkylation-sensitive cells and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>AGT transformation (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer resistance to Alkylation-sensitive cells and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>GAT transformation (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer resistance to Alkylation-sensitive cells and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT was considered to confer resistance to alkylation-sensitive cells by means of lumbar spine distortions.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that The STAT portion was considered to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) by means of lumbar spine distortions.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that The portion of the STATs are able to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase was considered to confer resistance to alkylation chemotherapies by means of lumbar spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkylguaning-DNA alkyltransferase may have the ability to confer resistance to alkyl ways through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT are able to confer resistance to alkylation through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity is able to be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity is considered conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the stability Stat5 phenotype in the presence of MG132 is able to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase conferred resistance to alkylation chemotherapies by means of spinal distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacements to Gly156 and Lys165 is considered as conferring resistance to 06-BG through spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by alkyguaning-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by alkylguaning-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is able to be conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity may have been conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with Stat5 to Stat1 by means of spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that substitutions to Gly156 and Lys165 would have conferred resistance to 06-BG by means of spinal distortions.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that transformation of GAT would confer resistance to alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation may have conferred resistance on Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transition are able to confer resistance to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The STAT portion may have the ability to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The STAT portion would have conferred specificity on a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs were able to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT can confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT have the ability to confer resistance to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase-DNA have the ability to confer resistance to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing the C-terminal with the Stat5 phenotype were able to confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing simply the C-terminal with the Stat5 phenotype would have conferred the Stat5 phenotype of stability in the presence of MG132 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been able to be conferred by replacing Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance may have been conferred by replacing Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by alkyltransferase of 06-alkyltransferase-DNA on alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to have been conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 is conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 will be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transformation of AGT was believed to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>In addition, The part of TASTs is not able to confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>In addition, gene variety would not confer increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>In addition, genetic variety may not confer an increased risk of diabetes to a tolC deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>In addition, six mutations does not confer resistance 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>In addition, the excessive expression of EvgA is not able to confer resistance to a strain with tolC failure.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>In addition, the part of the TASTs was not able to confer specificity in a strain with tolC failure.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>In addition, these mutations could not confer 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>In addition, these mutations was not able to confer resistance 06-BG in a strain with tolC failure.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>In addition, these mutations would not confer 06-BG resistant in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>In itself, 06-BG resistant is not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>In itself, gene variety will confer no increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>In itself, genetic variation will confer no increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>In itself, over expression of EvgA was believed to be not to confer resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>In itself, part of STATs is not able to confer specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>In itself, the part of the STATs will confer no specificity.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>In itself, the part of the TASTs would confer no specificity.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT on alkyltransferase of pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by The STAT portion on a MAPK substrate or a MAPK kinase (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Increased AGT levels are associated with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection will conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation may confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation will conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transition would confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replaceing Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 may have conferred resistance on 06-BG, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 would confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase-DNA will confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 may confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs are able to confer resistance to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), a higher risk of diabetes will be conferred for the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the excessive expression of EvgA would confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant would confer a higher risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the genetic variant have conferred a higher risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity is thought to be conferred by the part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), specificity can be conferred for The part of TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), a higher risk of diabetes is able to be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes could be conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes is able to be conferred by genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes is conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), increasing risk of diabetes was conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations and is able to confer the resistance resistant to Gly160His and Gly160Arg.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>That over expression of EvgA has conferred resistance for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>The STAT portion (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred specificity on a MAPK substrate or a MAPK kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>The STAT portion (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>The alkylguaning-DNA alkyltransferase (AGT) that is observed to confer resistance on alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance is able to be checked in A2 (Stat1) by alkylguaning-DNA alkyltransferase .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since resistance pot was conferred in Stat1 by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase can confer resistance in Stat1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrat kinase (MAPKAP) , since specificity can be conferred on Stat1 for The portion of the STATs .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>The human alkyl-alkylation-DNA alkyltransferase (AGT) that conferred resistance on alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>The increase in parallel AGT levels conferred from stat5 phenotype of stability in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>The increase in parallel AGT levels conferred the the Stat5 stability phenotype in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>The part of STATs may not have conferred specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT is thought to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT is thought to confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by substitutions in Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by substitutions to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by replacements in Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by replacements to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by AGT transition to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the portion of the STATs has the ability to confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with Stat5 would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by only C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>The rise of parallel AGT levels acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by just replacing C-terminus by Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was observed to confer resistance on alkylation routes and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer resistance on alkyl ways and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer resistance to alkylation pathways and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>alkyltransferase of 06-alkyltransferase of AGT conferred resistance to alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>alkyltransferase of 06-alkyltransferase of AGT may confer resistance to alkylation has not been determined.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>genetic variety can confer an increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkylation pathways and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>increasing risk of diabetes in a tolC-deficient strain is able to be conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>just replacing C-terminus by Stat5 (AGT) that can confer the stability phenotype Stat5 in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>just replacing C-terminus by Stat5 06 human (AGT) that conferred the stability phenotype Stat5 in the presence of MG132 over Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer the stability Stat5 phenotype in the presence of MG132 to Stat1 and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>replacements to Gly156 and Lys165 (AGT) is thought to confer resistance on 06-BG was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>replacements to Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to 06-BG and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>replacing Gly156 and Lys165 (AGT) that conferred resistance over 06-BG was therefore an active target for anti-drugs.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>replacing simply the C-terminal with Stat5 (AGT) that can confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>resistance 06-BG in a strain with tolC deficiencies is able to be conferred by resistance.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>resistance 06-BG in a tolC-deficient strain is able to be conferred by resistance.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>resistance can be conferred by human 06-alkylguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation pathways.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>resistance can be conferred by no by overexpression of EvgA.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>resistance for alkylation-sensitive cells has been conferred by transformation of AGT.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>resistance for alkylation-sensitive cells was conferred by transfection of AGATT.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>resistance is able to confer replacements in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>resistance was confer as replaceing Gly156 and Lys165, which directly reverses the endogenous 06-BG to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>six mutations was able to confer resistance 06-BG to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>six mutations was not able to confer 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>specificity has the ability to confer The STAT portion (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>specificity in a tolC-deficient strain may have been conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>specificity is conferred by The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in either a MAPK or a MAPK substrat kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>specificity will be conferred by the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>specificity would be conferred by the portion of the STATs, which directly reverses the endogenous alkylation in the position of 06-guanin, in either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>the Stat5 phenotype in the presence of MG132 was conferred by replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>the Stat5 phenotype of stability in the presence of MG132 for Stat1 was conferred by replacing simply the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>the Stat5 phenotype of stability in the presence of MG132 for State1 is conferred by only C-terminal substitution for Stat5</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>the excessive expression of EvgA might have not conferred resistance.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>the part of STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>the part of STATs which confers specificity to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>the part of the STATs is considered to be no to confer specificity.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>the stability Stat5 phenotype in the presence of MG132 would be conferred by just replacing the C-terminal with the Stat5 phenotype, which directly reverses the endogenous alkylation in the position of 06-guanin, in Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>these mutations may confer 06-BG resistant to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>these mutations might have not conferred resistance of 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that only the C-terminal substitution for Stat5 may confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that only the C-terminal substitution for Stat5 was considered to confer the Stat5 phenotype in the presence of MG132 to Stat1 by means of lumbar spine distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the part of STATs conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) by means of spinal distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the part of STATs is considered as conferring specificity to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability phenotype Stat5 in the presence of MG132 is conferred by which simply replaces C-terminus for Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that which simply replaces C-terminus for Stat5 was able to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 by spine distortions.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that the part of STATs could confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) through distortions of the lumbar vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that part of STATs is thought to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity was believed to be conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 has been able to be conferred by only the C-terminal substitution for Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>In addition, chapter changes or change of frame in the coding sequence or by splice variants is not able to confer motors of loss of function to a strain with tolC failure.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>In addition, nonsense or frameshift alteration in the coding sequence or by splice variants would not confer function loss mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>In addition, senseless alteration or frame change after encoding or splice variants does not confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>In addition, senseless change or change in frame in the coding sequence or for splice variants could not confer function loss change to a strain with tolC problems.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>In itself, changes in function loss is not conferred by changes in frame in the coding sequence or by splice variants.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>In itself, movement of loss of function would be conferred no by no change in meaning or change in table in the coding sequence or by splice variants.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>In itself, mutations of loss of functions was not able to be conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>In itself, no significant changes or changes in the frame in the coding sequence or for splice variants conferred no loss of function changes.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>In itself, the Stat5 phenotype of stability in the presence of MG132 is not conferred by replacing simply the C-terminal with Stat5.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Increased AGT levels are associated with acquired alkylation pathways resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by human 06-alkylguaning-DNA alkyltransferase on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Increased AGT levels in parallel with acquired Stat1 the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and which simply replaces C-terminus for Stat5 conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs were observed to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 conferred resistance on State1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Increased human 06-alkylguaning-DNA alkyltransferase levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Increased only the C-terminal substitution for Stat5 levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by AGT to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Increased the STAT portion levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT could confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Increased the part of STATs levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>It was believed that non-sense change or frame deviation in the coding sequence or for splice variants would confer no to movement of loss of function.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the change of loss of function could be conferred for no-sense change or change of frame in the coding sequence or to splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss mutations was able to be conferred for senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance could be conferred for human 06-alkylguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), without change of meaning or change of table in the coding sequence or for splice variants could confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), mutations of loss of functions was able to be conferred to alterations of frame shift in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that function loss change was conferred for senseless change or change in frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants would confer function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), debarred or frame alterations in the encoding sequence or by splice variants was considered to confer mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 is considered to confer the the Stat5 phenotype of stability in the presence of MG132 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), changes in function loss can be conferred by changes in frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss engines has been conferred by no sense alterations or frame shifts in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that movement of loss of function is conferred by no change in meaning or change in table in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance is conferred by replacing Gly156 and Lys165 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), movement of loss of function was conferred by non-sense change or frame deviation in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no-sense alterations or frame shifts in the encoding sequence or for splice variants is considered to confer the resistance function loss motion (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alterations or frame change in the encoding sequence or for splice variants is considered to confer the resistance function loss mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or to splice variants conferred the function loss mutations resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no sense alterations or frame change in the encoding sequence or for splice variants may confer the resistance function loss motion.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no-sense alterations or frame shifts in the encoding sequence or for splice variants and is able to confer the resistance function loss motion.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>That alkyguaning-DNA alkyltransferase is able to confer resistance for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>That alterations of discount or frame change in the encoding sequence or for splice variants has the ability to confer mutations of loss of functions for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>That debarred or frame alterations in the encoding sequence or by splice variants could confer mutations of loss of functions for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>That the part of STATs can confer specificity for a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) has not been determined.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>The rise in parallel AGT levels acquired State1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>The rise in parallel AGT levels has acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>The rise in parallel AGT levels has acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>The rise in parallel substitutions in Gly156 and Lys165 levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT can confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>The rise of only the C-terminal substitution for Stat5 levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by AGT on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>The rise of parallel AGT levels acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>The rise of parallel alkyguaning-DNA alkyltransferase levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is able to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>The rise of parallel the STAT portion levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT was able to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is able to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>chapter changes or change of frame in the coding sequence or by splice variants was not able to confer motors of loss of function.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>frame shift alterations in the encoding sequence or by splice variants could confer function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>function loss engines in a tolC problem strain has been conferred by discount alterations or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>function loss engines is thought to be conferred by M-NG (not) for without significant changes or frame deviations in the coding sequence or for splice variants.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>function loss motion was considered as not conferred by no sense alterations or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>loss of function mutation in a strain with tolC deficiencies is able to be conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>mutations of loss of functions is thought to be conferred by M-NG (not) for senseless alteration or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>no significant change or change in table in the coding sequence or for splice variants will confer change in function loss.</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>no-sense change or change of frame in the coding sequence or to splice variants may not have conferred change of loss of function.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>non-sense change or deviation of frame in the coding sequence or for splice variants would confer movement of loss of function.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants might have not conferred loss of mutation function.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>senseless change or change in frame in the coding sequence or for splice variants is able to confer function loss change to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>specificity is conferred by the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>specificity may have been conferred by the part of STATs (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>specificity was confer as the part of STATs, which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>substitutions in Gly156 and Lys165 may not have conferred resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>the STAT portion which confers specificity to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>the Stat5 phenotype in the presence of MG132 has the ability to confer only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>the part of STATs (AGT) which conferring specificity on a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) is therefore an active target of anti-tank drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>the part of STATs (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) in 06 guanin positions, has the ability to confer specificity to alkylation and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to the position 06 of guanin, could confer specificity to alkylation and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) at the position of 06 guanin, was observed to confer specificity to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>without significant changes or frame deviations in the coding sequence or for splice variants can be conferred to function loss engines.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
